Pfizer, Genzyme deal with recalls over labeling issues

Labeling problems recently tripped up two big drugmakers, Pfizer and Genzyme, which are both recalling products after they discovered missing or incorrect expiration dates. In Pfizer’s case, it is the second recall this year tied to a labeling issue.

According to the most recent FDA Enforcement report, Pfizer ($PFE) is recalling 1,316 bottles of its conjugated estrogen product, Premarin, because the labels on the 1,000-count bottles say they expire in November 2017 instead of September 2017. The recall began on September 15.

Earlier this year, Pfizer voluntarily recalled 63,636 bottles of adult Robitussin Peak Cold Cough & Chest Congestion DM Liquid in 8-oz. bottles because some bottles were mislabeled Adult Robitussin Maximum Strength Nighttime Cough DM.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

In the case of Genzyme, the biotech unit of Sanofi ($SNY), the company is recalling 9,530 vials of its stem cell transplant drug Mozobil because expiration dates may be missing from the vials. That recall, classified this week, began last month. 

Earlier this year, Genzyme voluntarily recalled more than 36,000 vials of its thyroid cancer drug Thyrogen from the U.S., Puerto Rico, Malaysia, Taiwan, Brazil and Israel. In that case, glass particles were found in some of the drugs when they were reconstituted.

- access the recalls here

Related Articles: 
Pfizer recalls mislabeled bottles of adult Robitussin 
Sanofi Genzyme recalling Thyrogen from U.S., other countries

Read more on

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.